Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.53% | 190.53 | 1.2% | $558.24m | |
| GILD | Gilead Sciences, Inc. | -0.25% | 70.74 | 0.9% | $494.49m | |
| BIIB | Biogen Inc. | -1.47% | 314.39 | 1.3% | $441.96m | |
| CELG | Celgene Corporation | -0.84% | 69.65 | 1.2% | $414.90m | |
| ILMN | Illumina, Inc. | -0.97% | 308.15 | 3.5% | $394.41m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.57% | 336.74 | 2.6% | $277.36m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -3.76% | 163.91 | 1.9% | $261.15m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.74% | 116.46 | 2.0% | $195.61m | |
| A | Agilent Technologies, Inc. | -1.14% | 63.61 | 1.5% | $166.24m | |
| EXAS | Exact Sciences Corporation | -1.66% | 68.26 | 25.3% | $147.18m | |
| LGND | Ligand Pharmaceuticals Incorporated | -0.65% | 147.46 | 23.3% | $142.67m | |
| SRPT | Sarepta Therapeutics, Inc. | -5.07% | 110.85 | 16.4% | $126.81m | |
| ECYT | Endocyte, Inc. | -0.04% | 23.57 | 2.0% | $120.21m | |
| INCY | Incyte Corporation | -0.26% | 63.57 | 2.5% | $112.11m | |
| NKTR | Nektar Therapeutics | 1.74% | 38.00 | 5.6% | $107.70m |
Company Profile
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.